BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: You JH. Novel oral anticoagulants vs warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.J Gen Intern Med. 2014;29:438-446. [PMID: 24132628 DOI: 10.1007/s11606-013-2639-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Sabir I, Khavandi K, Brownrigg J, Camm AJ. Oral anticoagulants for Asian patients with atrial fibrillation. Nat Rev Cardiol 2014;11:290-303. [DOI: 10.1038/nrcardio.2014.22] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
2 You J. Antimicrobial stewardship programs - cost-minimizing or cost-effective? Expert Opin Pharmacother 2015;16:155-7. [PMID: 25331093 DOI: 10.1517/14656566.2015.973854] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
3 Thanimalai S, Shafie AA, Ahmad Hassali MA, Sinnadurai J. Cost-Effectiveness of Warfarin Medication Therapy Adherence Clinic versus Usual Medical Clinic at Kuala Lumpur Hospital. Value Health Reg Issues 2018;15:34-41. [PMID: 29474176 DOI: 10.1016/j.vhri.2017.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 Magnuson EA, Vilain K, Wang K, Li H, Kwong WJ, Antman EM, Ruff CT, Giugliano RP, Cohen DJ; ENGAGE AF–TIMI 48 Trial Investigators. Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. Am Heart J 2015;170:1140-50. [PMID: 26678636 DOI: 10.1016/j.ahj.2015.09.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
5 Rose AJ, Park A, Gillespie C, Van Deusen Lukas C, Ozonoff A, Petrakis BA, Reisman JI, Borzecki AM, Benedict AJ, Lukesh WN, Schmoke TJ, Jones EA, Morreale AP, Ourth HL, Schlosser JE, Mayo-Smith MF, Allen AL, Witt DM, Helfrich CD, McCullough MB. Results of a Regional Effort to Improve Warfarin Management. Ann Pharmacother 2017;51:373-9. [PMID: 28367699 DOI: 10.1177/1060028016681030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Micieli A, Wijeysundera HC, Qiu F, Atzema CL, Singh SM. A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation. Med Decis Making 2016;36:366-74. [DOI: 10.1177/0272989x15593083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
7 Wang X, Chen H, E E, Wu J, Serna O, Paranjpe R, Abughosh S. Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res 2021;21:829-36. [PMID: 32703040 DOI: 10.1080/14737167.2020.1800457] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet. 2015;386:281-291. [PMID: 25777662 DOI: 10.1016/s0140-6736(15)60243-4] [Cited by in Crossref: 132] [Cited by in F6Publishing: 48] [Article Influence: 18.9] [Reference Citation Analysis]
9 Rose AJ, Delate T, Ozonoff A, Witt DM. Comparison of the Abilities of Summary Measures of International Normalized Ratio Control to Predict Clinically Relevant Bleeding. Circ Cardiovasc Qual Outcomes 2015;8:524-31. [PMID: 26330391 DOI: 10.1161/CIRCOUTCOMES.115.001768] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
10 Singh SM, Wijeysundera HC. Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation. Curr Cardiol Rep 2015;17:61. [PMID: 26081245 DOI: 10.1007/s11886-015-0618-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
11 Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Beard SM, Holmes DR. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure. J Am Coll Cardiol. 2015;66:2728-2739. [PMID: 26616031 DOI: 10.1016/j.jacc.2015.09.084] [Cited by in Crossref: 60] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
12 Ma H, Jian W, Xu T, He Y, Rizzo JA, Fang H. Quality of pharmacoeconomic research in China: A systematic review. Medicine (Baltimore) 2016;95:e5114. [PMID: 27741131 DOI: 10.1097/MD.0000000000005114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
13 Lam WW, Reyes MA, Seger JJ. Plasma Exchange for Urgent Apixaban Reversal in a Case of Hemorrhagic Tamponade after Pacemaker Implantation. Tex Heart Inst J 2015;42:377-80. [PMID: 26413023 DOI: 10.14503/THIJ-14-4424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
14 Miller JD, Ye X, Lenhart GM, Farr AM, Tran OV, Kwong WJ, Magnuson EA, Weintraub WS. Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US. Clinicoecon Outcomes Res 2016;8:215-26. [PMID: 27284259 DOI: 10.2147/CEOR.S98888] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
15 Rose AJ. Warfarin: not dead yet. J Gen Intern Med 2014;29:425-6. [PMID: 24249115 DOI: 10.1007/s11606-013-2708-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Caldeira D, Cruz I, Morgado G, Stuart B, Gomes C, Martins C, João I, Pereira H. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res Notes 2014;7:891. [PMID: 25491419 DOI: 10.1186/1756-0500-7-891] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
17 Gómez-Outes A, Suárez-Gea ML, García-Pinilla JM. Causes of death in atrial fibrillation: Challenges and opportunities. Trends Cardiovasc Med 2017;27:494-503. [PMID: 28602539 DOI: 10.1016/j.tcm.2017.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Baber U, Mastoris I, Mehran R. Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat Rev Cardiol 2014;11:693-703. [PMID: 25367652 DOI: 10.1038/nrcardio.2014.170] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
19 Weinberger J, Cipolle M. Optimal Reversal of Novel Anticoagulants in Trauma. Crit Care Clin 2017;33:135-52. [PMID: 27894493 DOI: 10.1016/j.ccc.2016.08.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
20 Rodwin BA, Desai NR. The Reply. Am J Med 2019;132:e723. [PMID: 31307679 DOI: 10.1016/j.amjmed.2019.05.029] [Reference Citation Analysis]
21 Noviyani R, Youngkong S, Nathisuwan S, Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, McKay G, Sritara P, Attia J, Thakkinstian A. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med 2021:bmjebm-2020-111634. [PMID: 34635480 DOI: 10.1136/bmjebm-2020-111634] [Reference Citation Analysis]
22 Hellenbart EL, Faulkenberg KD, Finks SW. Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag 2017;13:325-42. [PMID: 28860793 DOI: 10.2147/VHRM.S121661] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 9.6] [Reference Citation Analysis]
23 Oramasionwu CU, Bailey SC, Duffey KE, Shilliday BB, Brown LC, Denslow SA, Michalets EL. The association of health literacy with time in therapeutic range for patients on warfarin therapy. J Health Commun 2014;19 Suppl 2:19-28. [PMID: 25315581 DOI: 10.1080/10810730.2014.934934] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
24 Vijenthira A, Le Gal G, Castellucci LA, Carrier M. Defining time in therapeutic range for busy clinicians: frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin. Thromb Res 2014;134:584-6. [PMID: 25037497 DOI: 10.1016/j.thromres.2014.06.024] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Bode K, Hindricks G, Ten Berg JM, Whittaker P. Anticoagulant plus antiplatelet therapy for atrial fibrillation : Cost-utility of combination therapy with non-vitamin K oral anticoagulants vs. warfarin. Herz 2020;45:564-71. [PMID: 30209519 DOI: 10.1007/s00059-018-4747-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Djalali S, Valeri F, Gerber B, Meli DN, Senn O. Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. Clin Appl Thromb Hemost 2017;23:685-95. [PMID: 27056934 DOI: 10.1177/1076029616642514] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Muselík J, Urbanova M, Bartoníčková E, Palovčík J, Vetchý D, Czernek J, Janisova L, Velychkivska N, Franc A, Brus J. Structural Changes of Sodium Warfarin in Tablets Affecting the Dissolution Profiles and Potential Safety of Generic Substitution. Pharmaceutics 2021;13:1364. [PMID: 34575440 DOI: 10.3390/pharmaceutics13091364] [Reference Citation Analysis]
28 Eggebrecht L, Ludolph P, Göbel S, Panova-Noeva M, Arnold N, Nagler M, Bickel C, Lauterbach M, Hardt R, Cate HT, Lackner KJ, Espinola-Klein C, Münzel T, Prochaska JH, Wild PS. Cost saving analysis of specialized, eHealth-based management of patients receiving oral anticoagulation therapy: Results from the thrombEVAL study. Sci Rep 2021;11:2577. [PMID: 33510343 DOI: 10.1038/s41598-021-82076-9] [Reference Citation Analysis]
29 Hospodar AR, Smith KJ, Zhang Y, Hernandez I. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. Am J Cardiovasc Drugs 2018;18:317-25. [PMID: 29740750 DOI: 10.1007/s40256-018-0279-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Farsad BF, Abbasinazari M, Dabagh A, Bakshandeh H. Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study.J Clin Diagn Res. 2016;10:FC04-FC06. [PMID: 27790456 DOI: 10.7860/JCDR/2016/21955.8457] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
31 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
32 Kennedy C, Gabr A, McCormack J, Collins R, Barry M, Harbison J. The association between increasing oral anticoagulant prescribing and atrial fibrillation related stroke in Ireland. Br J Clin Pharmacol 2021. [PMID: 34131941 DOI: 10.1111/bcp.14938] [Reference Citation Analysis]
33 Oguz M, Lanitis T, Li X, Wygant G, Singer DE, Friend K, Hlavacek P, Nikolaou A, Mattke S. Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA. Appl Health Econ Health Policy 2020;18:533-45. [PMID: 31849021 DOI: 10.1007/s40258-019-00542-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Afzal SK, Hasan SS, Babar ZU. A systematic review of patient-reported outcomes associated with the use of direct-acting oral anticoagulants. Br J Clin Pharmacol 2019;85:2652-67. [PMID: 31077431 DOI: 10.1111/bcp.13985] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
35 García-Sempere A, Hurtado I, Bejarano D, Santa-Ana Y, Rodríguez-Bernal C, Peiró S, Sanfélix-Gimeno G. Group-based Trajectory Models to Assess Quality of INR Control and Its Association With Clinical Outcomes. Med Care 2020;58:e23-30. [PMID: 31764479 DOI: 10.1097/MLR.0000000000001253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Prochaska JH, Göbel S, Keller K, Coldewey M, Ullmann A, Lamparter H, Schulz A, Schinzel H, Bickel C, Lauterbach M, Michal M, Hardt R, Binder H, Espinola-Klein C, Lackner KJ, Ten Cate H, Münzel T, Wild PS. e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study. J Thromb Haemost 2017;15:1375-85. [PMID: 28457013 DOI: 10.1111/jth.13727] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
37 You JH. Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics 2015;16:1089-100. [PMID: 26230572 DOI: 10.2217/pgs.15.64] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]